Cultural Responsiveness Is Trial Infrastructure.

Representation goals do not create belonging. Patients experience inclusion through language, access, trusted relationships, and whether the study understands their lives.

Representation is an outcome. Responsiveness is the operating work.

Diversity targets describe who should be represented. They do not explain whether those people can find the study, trust its messengers, understand its demands, or participate without disproportionate burden.

FDA's draft Diversity Action Plan guidance focuses attention on enrollment goals and the measures used to achieve them. Those measures must reach beyond demographic advertising. They should address how the study operates for the populations it intends to include.

Translation without context is incomplete.

Accurate language access is essential, but comprehension also depends on examples, imagery, decision roles, risk concepts, and the way authority is understood. Some patients decide individually. Others expect family, caregivers, clinicians, faith leaders, or community members to participate in the process.

Culturally responsive design makes space for those relationships when the patient wants them involved. It also protects the patient's own voluntary choice and avoids assuming that every member of a demographic group shares the same beliefs.

Trust is built through institutions already trusted.

Community clinics, local physicians, patient organizations, pharmacies, cultural organizations, and community leaders may have relationships that a sponsor cannot reproduce through media. Partnership should begin before recruitment and include listening, co-design, and feedback.

These organizations are partners, not borrowed credibility. They need enough information and authority to challenge assumptions, identify harm, improve materials, and explain what will or will not work in their community.

Measure where the experience diverges.

Aggregate enrollment can hide different experiences across language, geography, age, race, ethnicity, disability, income, and digital access. Teams should examine awareness, response, comprehension, screening, handoff, burden, withdrawal, and support use across relevant groups.

Differences are signals for investigation, not evidence of patient deficiency. The operational question is which part of the study created a less accessible, less understandable, or less trustworthy path, and what change could correct it.

Sources.

1. FDA, Draft Guidance on Diversity Action Plans
2. FDA Oncology Center of Excellence, Fostering Diversity in Drug Development
3. Research Coordinator Perspectives on Underrepresented Recruitment
4. Mixed-Methods Study of Ethnic Minority Recruitment to Clinical Trials

About the author

Rebecca Schelkun

Vice President, Patient Readiness

Rebecca is Vice President of Patient Readiness at Jumo Health. She combines public health expertise in epidemiology and biostatistics with experience across health equity, patient advocacy, pediatrics, rare disease, and clinical trial strategy. At Jumo, she turns protocol demands and lived experience into education, decision support, and expectation alignment patients can use.